Option chain shows key data for ProMIS Neurosciences's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for ProMIS Neurosciences.

ProMIS Neurosciences (NASDAQ:PMN) Stock, Option Chain

ProMIS Neurosciences

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform-ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.

Penny,Stock,Investments,Taking,Off,Concept

Penny Stocks

Markets

EMMA

ProMIS Neurosciences And 2 Other Stocks Under $5 Executives Are Buying

Chi sale e chi scende: i maggiori movimenti nel pre-market di oggi

News

Pre-Market Outlook

Movers

Trading Ideas

ALLR

EFSH

FRGT

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

MYNA

OMEX

PGNY

SGLY

SMSI

TBIO

VEEA

VERO

WBUY

XCUR

Why Exicure Shares Are Trading Higher By Around 180%; Here Are 20 Stocks Moving Premarket

Long Ideas

Insider Trades

PAPL

Around $2M Bet On This Health Care Stock? Check Out These 3 Stocks Under $5 Insiders Are Aggressively Buying

ProMIS Neurosciences Inc. - Common Shares

ProMIS Neurosciences Inc

Perfect Moment Ltd

PERSEUS MINING LTD ORD by Perseus Mining Ltd

Perseus Mining Ltd

The Company previously presented its plan to file all delinquent periodic reports with the SEC, including the Form 10-Q for the period ended September 30, 2024, and requested an extension to do so at a hearing before the Nasdaq Hearings Panel. The Panel has not yet issued its decision following the hearing.

Real Good Food Company Gets Additional Delinquency Notice From Nasdaq Listing Qualifications Staff

Leslies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LESL#NASDAQ">LESL</a>) reported quarterly earnings of $0.02 per share which missed the analyst consensus estimate of $0.11 by 81.82 percent. The company reported quarterly sales of $397.900 million which missed the analyst consensus estimate of $405.197 million by 1.80 percent. This is a 7.97 percent decrease over sales of $432.370 million the same period last year.

Earnings

Earnings Misses

LESL

Leslies Q4 2024 Adj. EPS $0.02 Misses $0.11 Estimate, Sales $397.900M Miss $405.197M Estimate

Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) reported quarterly losses of $(1.36) per share. This is a 2.26 percent decrease over losses of $(1.33) per share from the same period last year. The company reported $14.61 million in sales this quarter. This is a 22.84 percent decrease over sales of $18.93 million the same period last year.

ENTA

CORRECTION: Enanta Pharma Q4 EPS $(1.36) Down From $(1.33) YoY, Sales $14.61M Down From $18.93M YoY

The earnings results for Blue Bird (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLBD#NASDAQ">BLBD</a>) for Q4 were made public on Monday, November 25, 2024 at 04:00 PM.
Here's a comprehensive overview of the announcement.
<h3>Earnings</h3>
Blue Bird missed estimated earnings by -16.0%, reporting an EPS of $0.77 versus an estimate of $0.92.
Revenue was up $47.25 million from the same period last year.
<h3>Previous Earnings Records</h3>
The company beat on EPS by $0.4 in the last quarter, resulting in a 0.0% increase share price change the following day.
Here's a look at Blue Bird's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.51</td>
<td>0.48</td>
<td>0.37</td>
<td>0.48</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.91</td>
<td>0.89</td>
<td>0.91</td>
<td>0.66</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>328.60M</td>
<td>298.41M</td>
<td>275.13M</td>
<td>290.11M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>333.37M</td>
<td>345.92M</td>
<td>317.66M</td>
<td>302.96M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Blue Bird <a href="https://www.benzinga.com/quote/BLBD/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BLBD

Blue Bird: Q4 Earnings Insights

The Q4 earnings report for Woodward (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) was released on Monday, November 25, 2024 at 04:00 PM.
Here's what investors need to know about the latest announcement.
<h3>Earnings</h3>
Woodward beat estimated earnings by 13.0%, reporting an EPS of $1.41 versus an estimate of $1.25.
Revenue was up $77.42 million from the same period last year.
<h3>Historical Earnings Summary</h3>
The company beat on EPS by $0.12 in the last quarter, resulting in a 17.0% drop share price change the following day.
Here's a look at Woodward's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.51</td>
<td>1.32</td>
<td>1.10</td>
<td>1.31</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.63</td>
<td>1.62</td>
<td>1.45</td>
<td>0.84</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>853.82M</td>
<td>807.00M</td>
<td>748.29M</td>
<td>765.35M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>847.69M</td>
<td>835.34M</td>
<td>786.73M</td>
<td>777.07M</td>
</tr>
</tbody>
</table>

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Guidance</h3>
Woodward management provided guidance for FY 2025, expecting earnings between $5.75 and $6.25 per share.
To track all earnings releases for Woodward <a href="https://www.benzinga.com/quote/WWD/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Woodward Earnings Review: Q4 Summary

Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) announced its Q4 earnings on Monday, November 25, 2024 at 04:01 PM.
Here's a breakdown of the earnings report.
<h3>Earnings</h3>
Enanta Pharma beat estimated earnings by 4.0%, reporting an EPS of $-1.36 versus an estimate of $-1.41.
Revenue was down $4.33 million from the same period last year.
<h3>Performance in Previous Earnings</h3>
During the previous quarter, the company beat on EPS by $0.38, leading to a 1.0% increase share price change the next day.
Here's a look at Enanta Pharma's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.45</td>
<td>-1.33</td>
<td>-1.19</td>
<td>-2</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.07</td>
<td>-1.47</td>
<td>-1.58</td>
<td>-1.33</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>17.18M</td>
<td>16.52M</td>
<td>21.28M</td>
<td>17.50M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>17.97M</td>
<td>17.05M</td>
<td>18.00M</td>
<td>18.93M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Enanta Pharma <a href="https://www.benzinga.com/quote/ENTA/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Breakdown: Enanta Pharma Q4

As of September 30, 2024, Alector has $457.2 million in cash, cash equivalents, and investments, which the company continues to expect will provide runway through 2026. Alector plans to provide guidance for 2025 during its fourth-quarter and full-year earnings conference call.

ALEC

Alector Expects Cash & Equivalents To Provide Runway Through 2026

WIIM

Agilent Technologies shares are trading lower after the company provided Q1 and FY25 adjusted EPS and revenue guidance below analyst expectations.

CENT

CENTA

Central Garden & Pet shares are trading lower after the company reported Q4 sales that missed analyst estimates, despite better-than-expected adjusted EPS.

The term "metaverse" was one of the top trends in 2021 with companies and cryptocurrencies related to the term seeing soaring valuations. While interest in the metaverse has fallen off in recent years, two cryptocurrencies with ties to the metaverse were among the <a href="https://www.benzinga.com/money/top-metaverse-coins">top gainers of the past week.</a>
What Happened: The Sandbox (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sand/usd">SAND</a>) and Decentraland (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/mana/usd">MANA</a>) cryptocurrencies are among the biggest movers of the last week, gaining 107% and 57%, respectively, over the last seven days, which comes as interest in the metaverse <a href="https://www.benzinga.com/news/events/24/11/42172802/nfts-metaverse-derided-rightly-but-experts-see-bright-future-ahead" target="_blank" rel="noopener">could be growing once again.</a>
The two coins are connected to virtual worlds and were high performers in 2021 and 2022 as interest in virtual land and metaverse-related companies and cryptocurrencies soared.
While the prices of the coins are down sharply from all-time highs set in November 2021, the recent gains have the coins hitting new levels not seen in some time.
The Sandbox coin is up 27% over the last day to $0.7294, making it one of the top gainers in the last 24 hours. The coin has traded between $0.2098 and $0.8493 over the last year, with the yearly high recently hit in the past week. The all-time high for the coin is $8.44, set on Nov. 25, 2021.
The Decentraland coin is up 11% over the last day to $0.6532, making it one of the top gainers in the last 24 hours. The coin has traded between $0.2181 and $0.8185 over the last year. Over the past week, it hit new monthly highs of $0.7731. The all-time high for the coin is $5.90, set on Nov. 25, 2021.
Investors who bought the metaverse-related coins in 2021 could have generated a nice profit throughout the year and into 2022. Here's a look at their stake if they held.
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41908812/if-you-invested-100-in-dogecoin-when-the-meme-coin-launched-heres-how-much-youd-have-today">If You Invested $100 In Dogecoin When The Meme Coin Launched, Here&#8217;s How Much You&#8217;d Have Today</a>
Investing $1,000 in SAND, MANA: The Sandbox coin&nbsp;<a href="https://coinmarketcap.com/currencies/the-sandbox/" target="_blank" rel="noreferrer noopener">traded&nbsp;</a>at a high of $0.0379 on Jan. 1, 2021. A $1,000 investment in SAND on the first day of the year could have bought 26,385.22 SAND coins.
The $1,000 investment would be worth $19,245.38 today based on a current price of $0.7294, up 1,824.5% since the start of 2021.
The Decentraland coin&nbsp;<a href="https://coinmarketcap.com/currencies/decentraland/" target="_blank" rel="noreferrer noopener">traded&nbsp;</a>at a high of $0.0839 on Jan. 1, 2021. A $1,000 investment in MANA on the first day of the year could have bought 11,918.95 MANA coins.
The $1,000 investment would be worth $7,785.46 today based on a current price of $0.6532, up 678.5% since the start of 2021.
What's Next: The metaverse was a big topic in 2021 with the launch of virtual land from several companies, the launch of the Roundhill Ball Metaverse ETF and <a href="https://www.benzinga.com/general/education/24/10/41163360/if-you-invested-1-000-in-facebook-stock-when-mark-zuckerberg-changed-name-to-meta-heres-how-muc">the announced rebrand</a> of Facebook to Meta Platforms.
Tesla CEO Elon Musk <a href="https://www.benzinga.com/markets/cryptocurrency/21/12/24718726/is-the-metaverse-a-marketing-buzzword-or-multitrillion-dollar-opportunity-elon-musk-cathie">called the metaverse</a> a "marketing buzzword" previously.
Ark Invest CEO Cathie Wood took the other side and said the metaverse was in the early stages of development at the time.
"It's a big idea that will probably infiltrate – just like technology is, anyway – every sector in ways that we cannot even imagine right now," Wood said.
She said the metaverse could be a multitrillion-dollar opportunity, a stark contrast from Musk saying the metaverse is a marketing buzzword.
Fast-forward to today, and skepticism around the metaverse has grown, with some use cases losing their luster and excitement waning in recent years. Yet, metaverse and gaming tokens have recently surged as top crypto gainers, sparking renewed investor interest in the sector&#8217;s potential revival.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42146874/if-you-invested-1000-in-solana-when-sam-bankman-fried-was-arrested-heres-how-much-youd-have-today">If You Invested $1,000 In Solana When Sam Bankman-Fried Was Arrested, Here&#8217;s How Much You&#8217;d Have Today</a></li>
</ul>
This article was previously published by Benzinga and has been updated.
Photo: Koshiro K/Shutterstock.com

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$MANA

$SAND

If You Invested $1,000 In The Sandbox And Decentraland Coins On Jan. 1, 2021, Here's How Much You'd Have Now

Alector Says It Is Reducing Its Workforce By Approximately 17%, Stopping Long-term Extension Study Based Upon AL002 INVOKE-2 Phase 2 Trial Results

Zoom shares are trading lower following Q3 earnings.

Alector shares are trading lower after the company announced that the INVOKE-2 Phase 2 clinical trial evaluating the safety and efficacy of AL002 in individuals with early Alzheimer's disease failed to meet its primary endpoint.

Pennant Park Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNNT#NYSE">PNNT</a>) reported quarterly earnings of $0.75 per share which beat the analyst consensus estimate of $0.72 by 4.17 percent.

Earnings Beats

PNNT

Pennant Park Investment FY 2024 GAAP EPS $0.75 Beats $0.72 Estimate

Stock Repurchase Authorization: In November 2024, Zoom's Board of Directors authorized the repurchase of an additional $1.2 billion of Zoom's outstanding Class A common stock. This authorization is in addition to the amount remaining under the prior authorization for the share repurchase program, for a total of approximately $2.0 billion remaining to be repurchased.
Repurchases of Zoom's Class A common stock may be effected, from time to time, either on the open market (including pre-set trading plans), in privately negotiated transactions, and other transactions in accordance with applicable securities laws.
The timing and the amount of any repurchased Class A common stock will be determined by Zoom's management based on its evaluation of market conditions and other factors. The repurchase program will be funded using Zoom's working capital. Any repurchased shares of Class A common stock will be retired. The repurchase program does not obligate Zoom to acquire any particular amount of Class A common stock, and the repurchase program may be suspended or discontinued at any time at Zoom's discretion.

Buybacks

In November 2024, Zoom's Board Of Directors Authorized The Repurchase Of An Additional $1.2B Of Outstanding Class A Common Stock; Authorization Is In Addition To The Amount Remaining Under The Prior Authorization For The Share Repurchase Program, For A Total Of ~$2B Remaining To Be Repurchased

Alector Reports Results From AL002 INVOKE-2 Phase 2 Trial In Individuals With Early Alzheimer's Disease; Says AL002 Failed To Meet Primary Endpoint

Financial Outlook:&nbsp;Zoom is providing the following guidance for its fourth quarter of fiscal year 2025 and its full fiscal year 2025.
<ul>
<li>Fourth Quarter Fiscal Year 2025: Total revenue is expected to be between $1.175 billion and $1.180 billion and revenue in constant currency is expected to be between $1.174 billion and $1.179 billion. Non-GAAP income from operations is expected to be between $443.0 million and $448.0 million. Non-GAAP diluted EPS is expected to be between $1.29 and $1.30 with approximately 315 million weighted average shares outstanding.</li>
<li>Full Fiscal Year 2025: Total revenue is expected to be between $4.656 billion and $4.661 billion and revenue in constant currency is expected to be between $4.661 billion and $4.666 billion. Full fiscal year non-GAAP income from operations is expected to be between $1.813 billion and $1.818 billion. Full fiscal year non-GAAP diluted EPS is expected to be between $5.41 and $5.43 with approximately 315 million weighted average shares outstanding. Full fiscal year free cash flow is expected to be between $1.580 billion and $1.620 billion.</li>
</ul>
The EPS and share count figures do not include the impact from the share repurchase authorization discussed below.
Additional information on Zoom's reported results, including a reconciliation of the non-GAAP results to their most comparable GAAP measures, is included in the financial tables below. A reconciliation of non-GAAP guidance measures to corresponding GAAP measures is not available on a forward-looking basis without unreasonable effort due to the uncertainty of expenses that may be incurred in the future, although it is important to note that these factors could be material to Zoom's results computed in accordance with GAAP.
A supplemental financial presentation and other information can be accessed through Zoom's investor relations website at investors.zoom.us.

Guidance

Zoom Video Communications Sees Q4 EPS $1.29-$1.30 Vs $1.28 Est.; Revenue $1.175B-$1.18B Vs $1.17B Est.; FY25 EPS $5.41-$5.43 Vs $5.35 Est.; Revenue $4.656B-$4.661B Vs $4.64B Est.

Agilent Technologies Sees Q1 Adj. EPS $1.25-$1.28 Vs $1.37 Est.; Revenue $1.65B-$1.68B Vs $1.697B Est.

The Company expects to grant the underwriters a 30-day option to purchase up to 2.70 million additional shares of its common stock.
The Company intends to use the net proceeds of this offering together with cash on hand, including from recent sales under the Company's "at the market" offering program, to repay the $478.0 million mortgage loan with a fixed effective interest rate of approximately 9.0% and which is secured by its Washington Square property.

Offerings

Macerich Commences Public Offering Of 18M Shares Of Common Stock

PFLT

PennantPark Floating Rate Capital Ltd. Q4 Core NII Per Share $0.32

ProMIS Neurosciences (PMN) has shared an update. ProMIS Neurosciences Inc. reported promising preliminary results from its Phase 1a clinical trial ...

ProMIS Neurosciences Advances in Alzheimer's Treatment Trial

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
ProMIS Neurosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/pmn-stock-quote/">PMN</a>) just reported results for the second quarter of 2024.<ul><li>ProMIS Neurosciences reported earnings per share of -13 cents. This was above the analyst estimate for EPS of -14 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/pmn-stock-earnings-promis-neurosciences-for-q2-of-2024/">PMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

PMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q2 2024

In a report released yesterday, Thomas Shrader from BTIG maintained a Buy rating on ProMIS Neurosciences (PMN – Research Report), with a price targ...

Buy Rating on ProMIS Neurosciences Backed by Innovative Alzheimer's Treatment and Strong Financials

ProMIS Neurosciences GAAP EPS of -$0.13

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to dive into the biggest pre-market stock movers for Monday morning with all of the latest news affecting shares today!



Moving stocks are new patents, insider buying, a company name change and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>PS International Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/psig-stock-quote/">PSIG</a>) stock is rocketing more than 81% alongside heavy pre-market trading.</li>



<li>Ainos (NASDAQ:<a href="https://investorplace.com/stock-quotes/aimd-stock-quote/">AIMD</a>) shares are soaring over 47% after <a href="https://www.nasdaq.com/press-release/ainos-secures-exclusive-multi-regions-invention-patent-licenses-strategic-partner">securing new patent licenses</a>.</li>



<li>LogicMark (NASDAQ:<a href="https://investorplace.com/stock-quotes/lgmk-stock-quote/">LGMK</a>) stock is surging more than 38% alongside details of an upcoming <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318511278&amp;type=PDF&amp;symbol=LGMK&amp;cdn=5653ec5b97d2382396937934a20579e2&amp;companyName=LogicMark+Inc.&amp;formType=PRE+14A&amp;formDescription=Preliminary+proxy+statement+providing+notification+matters+to+be+brought+to+a+vote&amp;dateFiled=2024-08-09">special shareholder meeting</a>.</li>



<li>VS Media (NASDAQ:<a href="https://investorplace.com/stock-quotes/vsme-stock-quote/">VSME</a>) shares are gaining over 25% despite a lack of news this morning.</li>



<li>Genius (NYSEMKT:<a href="https://investorplace.com/stock-quotes/gns-stock-quote/">GNS</a>) stock is increasing more than 19% <a href="https://www.nasdaq.com/press-release/genius-group-founder-ceo-roger-james-hamilton-purchase-10-million-shares-2024-08-09">on insider buying</a>.</li>



<li>FSD Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/huge-stock-quote/">HUGE</a>) shares are rising over 19% on <a href="https://www.nasdaq.com/press-release/fsd-pharma-announces-share-consolidation-and-name-change-2024-08-09">share consolidation and name change plans</a>.</li>



<li>ProMIS Neurosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/pmn-stock-quote/">PMN</a>) stock is climbing more than 17% this morning.</li>



<li>ConnectM Technology (NASDAQ:<a href="https://investorplace.com/stock-quotes/cntm-stock-quote/">CNTM</a>) shares are heading over 17% higher without any clear news today.</li>



<li>BioVie (NASDAQ:<a href="https://investorplace.com/stock-quotes/bivi-stock-quote/">BIVI</a>) stock is jumping more than 15% on Monday morning.</li>



<li>Portage Biotech (NASDAQ:<a href="https://investorplace.com/stock-quotes/prtg-stock-quote/">PRTG</a>) shares are up over 14% this morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>iLearningEngines (NASDAQ:<a href="https://investorplace.com/stock-quotes/aile-stock-quote/">AILE</a>) stock is plummeting more than 27% after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318511870&amp;type=PDF&amp;symbol=AILE&amp;cdn=8f0ca76b44522478ea48d6b3e52f5445&amp;companyName=iLearningEngines+Inc.&amp;formType=EFFECT&amp;formDescription=Notice+of+Effectiveness&amp;dateFiled=2024-08-09">pricing a public offering</a>.</li>



<li>Meta Materials (NASDAQ:<a href="https://investorplace.com/stock-quotes/mmat-stock-quote/">MMAT</a>) shares are diving over 17% after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318508874&amp;type=PDF&amp;symbol=MMAT&amp;cdn=747b3fffafae953c1fe1c54f998009fd&amp;companyName=Meta+Materials+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-08-09">filing for bankruptcy</a>.</li>



<li>Sonoma Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/snoa-stock-quote/">SNOA</a>) stock is tumbling more than 15% after <a href="https://finance.yahoo.com/news/sonoma-pharmaceuticals-first-quarter-2025-120225512.html">missing fiscal Q1 2025 earnings estimates</a>.</li>



<li>Tenon Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/tnon-stock-quote/">TNON</a>) shares are taking an over 15% beating despite any clear news this morning.</li>



<li>Humacyte (NASDAQ:<a href="https://investorplace.com/stock-quotes/huma-stock-quote/">HUMA</a>) stock is sliding more than 13% <a href="https://www.stocktitan.net/news/HUMA/humacyte-announces-fda-communication-of-additional-time-required-to-5oxy7ry3qlgj.html">on an update</a> from the Food and Drug Administration (FDA).</li>



<li>Aditxt (NASDAQ:<a href="https://investorplace.com/stock-quotes/adtx-stock-quote/">ADTX</a>) shares are falling over 12% on a <a href="https://www.nasdaq.com/press-release/aditxt-announces-12-million-registered-direct-offering-priced-market-under-nasdaq">registered direct offering</a>.</li>



<li>CareMax (NASDAQ:<a href="https://investorplace.com/stock-quotes/cmax-stock-quote/">CMAX</a>) stock is dropping close to 12% on a <a href="https://finance.yahoo.com/news/caremax-inc-cmax-reports-q2-224503059.html">Q2 loss and revenue miss</a>.</li>



<li>Big Tree Cloud (NASDAQ:<a href="https://investorplace.com/stock-quotes/dsy-stock-quote/">DSY</a>) shares are decreasing more than 10% <a href="https://www.nasdaq.com/press-release/big-tree-cloud-holdings-limited-receives-nasdaq-notification-regarding-minimum-market">with a delisting notice</a>.</li>



<li>Azitra&nbsp;(NYSEMKT:<a href="https://investorplace.com/stock-quotes/aztr-stock-quote/">AZTR</a>) stock is slipping over 10% this morning.</li>



<li>Bright Minds Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/drug-stock-quote/">DRUG</a>) shares close out our pre-market stock movers down more than 10% today.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/08/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-monday-aug-12th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

ProMIS Neurosciences files to sell 56.51M common shares for holders

ProMIS Neurosciences ( ($PMN) ) just unveiled an announcement. ProMIS Neurosciences Inc. has officially appointed Neil Warma as its permanent Presi...

ProMIS Neurosciences Names Neil Warma Permanent CEO

ProMIS Neurosciences (PMN) presented positive results from all five cohorts from the Phase 1a, single ascending dose clinical trial of its lead pro...

ProMIS Neurosciences presents data from PMN310 Phase1a trial

"We made significant progress in the third quarter, highlighted by the positive results from our first-in-human Phase 1a clinical trial of PMN310 a...

ProMIS Neurosciences reports Q3 EPS 31c vs (19c) last year

ProMIS Neurosciences GAAP EPS of $0.31 beats by $0.38

ADTX

AILE

AIMD

AZTR

BIVI

CMAX

CNTM

DRUG

HUGE

HUMA

LGMK

MMAT

PRTG

PSIG

SNOA

TNON

VSME

Press Releases

ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial

ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer's Association International Conference

ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024

ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology

ProMIS Neurosciences Announces Second Quarter 2024 Financial Results and Recent Highlights

ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

ProMIS Neurosciences to Showcase PMN310's Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences

ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer's Disease Conference

ProMIS Neurosciences to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights

TSX:PMN

BTIG

Comments

ProMIS Neurosciences

ProMIS Neurosciences (PMN) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga